March 6, 2025

Alverno Laboratories has announced several important updates in Q1 2025 concerning tests performed by Quest Diagnostics. Effective December 23, 2024, Myoglobin, Urine now requires specimens to be submitted in specialized myoglobin urine transport tubes, available through the Supply Request Form on AlvernoLabs.com. For Soluble Transferrin Receptor, plasma collected in EDTA (lavender-top) tubes is no longer accepted; instead, serum in SST tubes or plasma in sodium/lithium heparin (green-top) tubes should be used. Additionally, as of January 13, 2025, Quest Diagnostics will discontinue individual anti-fungal susceptibility tests for yeast, recommending a comprehensive yeast susceptibility panel as the alternative. In February 2025, further updates include the discontinuation of the Toxicology Urine Drug Testing (Quest 91359) in favor of Quest test 11877, a change in specimen requirements for Lead, Whole Blood to a 3 mL Royal Blue Trace Element K2 EDTA tube, and modifications to the Influenza A and B Culture, Rapid Method and Viral Respiratory, Rapid Culture with Reflex tests regarding ordering and specimen collection.